インサイチュハイブリダイゼーション市場- 世界の産業規模、シェア、動向、機会、予測、製品別、技術別、用途別、エンドユーザー別、地域別、競合別、2020-2030年

インサイチュハイブリダイゼーション（ISH）の世界市場は、2024年に18億8,000万米ドルと評価され、予測期間中にCAGR 7.54％で成長し、2030年には29億1,000万米ドルに達すると予測されています。

ISHは、組織サンプル内の特定の核酸配列を正確に検出できることから、分子診断や生物医学研究において不可欠なツールとして認知されつつあります。特に腫瘍学や遺伝性疾患において、正確かつ早期に病気を発見したいという需要が市場の成長を後押ししています。ISHは遺伝子発現パターンや変異の詳細な可視化を可能にし、個別化医療戦略の要となっています。

自動染色プラットフォームや高解像度イメージングなどの技術革新により、ISHの使いやすさと信頼性が向上し、臨床検査室や研究機関での採用が広がっています。マルチプレックスアッセイの開発やプローブデザインの改良により、複数の遺伝子ターゲットの同時検出が可能になり、診断効率と患者の転帰が改善されつつあります。プレシジョン・メディシンの進展に伴い、標的治療の選択肢を提供する上でISHの関連性が拡大し、最新の診断学や医薬品開発における役割が強化されつつあります。

市場促進要因

がんおよび遺伝子疾患の発生率の上昇

主な市場課題

ISH技術と試薬の高コスト

主な市場動向

個別化医療との統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のインサイチュハイブリダイゼーション市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（機器、消耗品・アクセサリ、ソフトウェア、サービス）
  • 技術別（蛍光in situハイブリダイゼーション、発色in situハイブリダイゼーション）
  • 用途別（がん、細胞遺伝学、感染症、神経科学、免疫学、その他）
  • エンドユーザー別（病院・診断研究所、学術調査機関、製薬・バイオテクノロジー企業、契約調査機関、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のインサイチュハイブリダイゼーション市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のインサイチュハイブリダイゼーション市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のインサイチュハイブリダイゼーション市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のインサイチュハイブリダイゼーション市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのインサイチュハイブリダイゼーション市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Thermo Fisher Scientific, Inc.
• Abbott Laboratories Inc.
• PerkinElmer, Inc.
• Bio View Ltd.
• Agilent Technologies, Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Biotechne Corporation
• F. Hoffmann Roche AG
• Biocare Medical LLC

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global In Situ Hybridization (ISH) Market was valued at USD 1.88 Billion in 2024 and is projected to reach USD 2.91 Billion by 2030, growing at a CAGR of 7.54% during the forecast period. ISH is increasingly recognized as a vital tool in molecular diagnostics and biomedical research due to its capability to precisely detect specific nucleic acid sequences within tissue samples. The demand for accurate and early detection of diseases, particularly in oncology and genetic disorders, is driving market growth. ISH enables detailed visualization of gene expression patterns and mutations, making it a cornerstone in personalized medicine strategies.

Technological innovations such as automated staining platforms and high-resolution imaging are enhancing the usability and reliability of ISH, facilitating broader adoption in clinical laboratories and research institutions. Developments in multiplex assays and improved probe designs are enabling simultaneous detection of multiple genetic targets, improving diagnostic efficiency and patient outcomes. As precision medicine continues to advance, ISH's relevance in delivering targeted treatment options is expanding, strengthening its role in modern diagnostics and drug development.

Key Market Drivers

Rising Incidence of Cancer and Genetic Disorders

The increasing global burden of cancer and genetic diseases is a primary growth driver for the In Situ Hybridization market. According to the World Health Organization, cancer accounted for approximately 20 million new cases and 9.7 million deaths in 2022. Lung, breast, and colorectal cancers were among the most prevalent. These rising figures underscore the need for accurate molecular diagnostic tools that can provide specific and early detection. ISH, particularly Fluorescent In Situ Hybridization (FISH), plays a critical role in identifying genetic abnormalities, gene fusions, and chromosomal rearrangements within tissue samples, aiding in diagnosis, prognosis, and treatment planning.

Key Market Challenges

High Cost of ISH Technology and Reagents

The adoption of ISH techniques faces a significant hurdle due to the high costs associated with equipment and consumables. Advanced instruments such as hybridization systems and imaging platforms require substantial investment, which can be restrictive for smaller laboratories and facilities in developing regions. Additionally, reagents including specialized probes and buffers contribute to the overall expense, making frequent use of ISH less feasible in cost-sensitive healthcare environments. These cost barriers may limit the accessibility of high-precision diagnostics, particularly where budget constraints impact healthcare delivery.

Key Market Trends

Integration with Personalized Medicine

A notable trend shaping the ISH market is its growing integration into personalized medicine. ISH techniques, especially FISH, are being leveraged to detect genetic mutations and biomarkers that inform individualized treatment regimens. This alignment with precision healthcare is particularly prominent in oncology, where ISH supports targeted therapies by identifying specific molecular features of tumors. Companion diagnostics utilizing ISH allow clinicians to tailor treatments based on a patient's genetic profile, enhancing therapeutic efficacy and minimizing adverse effects. This synergy with precision medicine is reinforcing the value of ISH as a diagnostic standard in both clinical and research settings.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Abbott Laboratories Inc.
• PerkinElmer, Inc.
• Bio View Ltd.
• Agilent Technologies, Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Biotechne Corporation
• F. Hoffmann Roche AG
• Biocare Medical LLC

Report Scope:

In this report, the Global In Situ Hybridization Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In Situ Hybridization Market, By Product:

• Instruments
• Consumables & Accessories
• Software
• Services

In Situ Hybridization Market, By Technology:

• Fluorescent In Situ Hybridization
• Chromogenic In Situ Hybridization

In Situ Hybridization Market, By Application:

• Cancer
• Cytogenetics
• Infectious Diseases
• Neuroscience
• Immunology
• Others

In Situ Hybridization Market, By End User:

• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Others

In Situ Hybridization Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global In Situ Hybridization Market.

Available Customizations:

Global In Situ Hybridization Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global In Situ Hybridization Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Consumables & Accessories, Software, Services)
  • 5.2.2. By Technology (Fluorescent In Situ Hybridization, Chromogenic In Situ Hybridization)
  • 5.2.3. By Application (Cancer, Cytogenetics, Infectious Diseases, Neuroscience, Immunology, Others)
  • 5.2.4. By End User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America In Situ Hybridization Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States In Situ Hybridization Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico In Situ Hybridization Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada In Situ Hybridization Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe In Situ Hybridization Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France In Situ Hybridization Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany In Situ Hybridization Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom In Situ Hybridization Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy In Situ Hybridization Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain In Situ Hybridization Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific In Situ Hybridization Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China In Situ Hybridization Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India In Situ Hybridization Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea In Situ Hybridization Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan In Situ Hybridization Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia In Situ Hybridization Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America In Situ Hybridization Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil In Situ Hybridization Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina In Situ Hybridization Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia In Situ Hybridization Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa In Situ Hybridization Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa In Situ Hybridization Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia In Situ Hybridization Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE In Situ Hybridization Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Thermo Fisher Scientific, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Abbott Laboratories Inc.
• 14.3. PerkinElmer, Inc.
• 14.4. Bio View Ltd.
• 14.5. Agilent Technologies, Inc.
• 14.6. Merck KGaA
• 14.7. Bio-Rad Laboratories, Inc.
• 14.8. Biotechne Corporation
• 14.9. F. Hoffmann Roche AG
• 14.10. Biocare Medical LLC

15. Strategic Recommendations

16. About Us & Disclaimer